Anindita Chakrabarty

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Combination Therapy

Epithelial Mesenchymal Transition

Tyrosine Kinase

Top Venues

ACS pharmacology & translational science

RSC medicinal chemistry

Journal of natural products

This page only lists publications with an associated author ORCID identifier.

Publications

Shaista Haider, Shayantani Chakraborty, Goutam Chowdhury, Anindita Chakrabarty
Opposing Interplay between Nuclear Factor Erythroid 2-Related Factor 2 and Forkhead BoxO 1/3 is Responsible for Sepantronium Bromide's Poor Efficacy and Resistance in Cancer cells: Opportunity for Combination Therapy in Triple Negative Breast Cancer . ACS pharmacology & translational science 7 (5) (2024)
Shaista Haider, Shayantani Chakraborty, Goutam Chowdhury, Anindita Chakrabarty
Opposing Interplay between Nuclear Factor Erythroid 2-Related Factor 2 and Forkhead BoxO 1/3 is Responsible for Sepantronium Bromide's Poor Efficacy and Resistance in Cancer cells: Opportunity for Combination Therapy in Triple Negative Breast Cancer . ACS pharmacology & translational science 7 (5) (2024)
Shayantani Chakraborty, Dibyendu Mallick, Mausumi Goswami, Frederick Peter Guengerich, Anindita Chakrabarty, Goutam Chowdhury
The Natural Products Withaferin A and Withanone from the Medicinal Herb Withania somnifera Are Covalent Inhibitors of the SARS-CoV-2 Main Protease. Journal of natural products 85 (10) (2022)
Tasaduq Hussain Wani, Goutam Chowdhury, Anindita Chakrabarty
Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155). RSC medicinal chemistry 12 (4) (2021)